Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPD002
MIFTS: 22

Hepadnavirus Infection malady

Categories: Rare diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Hepadnavirus Infection

About this section

Aliases & Descriptions for Hepadnavirus Infection:

Name: Hepadnavirus Infection 50
Hepadnaviridae Infections 69

Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Hepadnavirus Infection

About this section
MalaCards based summary : Hepadnavirus Infection, also known as hepadnaviridae infections, is related to hepatocellular carcinoma and hepatitis. An important gene associated with Hepadnavirus Infection is TP53 (Tumor Protein P53). The drugs Ritonavir and Efavirenz have been mentioned in the context of this disorder. Affiliated tissues include liver and t cells.

Sources

Related Diseases for Hepadnavirus Infection

About this section

Diseases related to Hepadnavirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 10.0
2 hepatitis 10.0
3 hepatitis b 9.8
4 liver disease 9.8
5 t cell deficiency 9.8
6 viral hepatitis 9.8

Graphical network of the top 20 diseases related to Hepadnavirus Infection:



Diseases related to Hepadnavirus Infection
Sources

Symptoms & Phenotypes for Hepadnavirus Infection

About this section
Sources

Drugs & Therapeutics for Hepadnavirus Infection

About this section

Drugs for Hepadnavirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3 155213-67-5 392622
2
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
3
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
4
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
5
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
6
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
7
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
8
rituximab Approved Phase 4,Phase 3 174722-31-7 10201696
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
10
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
11
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
12
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
13
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
14
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
15
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 62304-98-7
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
17
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
18
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
19
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
20
Ethiodized oil Approved Phase 4,Phase 2 8008-53-5
21
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
22 Simethicone Approved Phase 4,Phase 3
23
Ethanol Approved Phase 4 64-17-5 702
24
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
25
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
26
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
27
Etravirine Approved Phase 4 269055-15-4 193962
28
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
29
Alprostadil Approved, Investigational Phase 4,Phase 2,Phase 1 745-65-3 149351
30
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
31
Lenograstim Approved Phase 4 135968-09-1
32
Methadone Approved Phase 4 76-99-3 4095
33
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
34 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
37
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
38
Maleic acid Experimental Phase 4,Phase 1 110-16-7 444266
39 Adefovir Phase 4,Phase 3,Phase 2,Phase 1
40 vitamin d Phase 4
41 Chlorhexidine gluconate Phase 4
42 Clevudine Phase 4,Phase 3,Phase 2
43 Prednisolone acetate Phase 4,Phase 2
44 Atorvastatin Calcium Phase 4 134523-03-8
45 Interleukin-2 Phase 4,Phase 3,Phase 1
46 interferons Phase 4,Phase 3,Phase 2,Phase 1
47 Analgesics Phase 4,Phase 3
48 glucocorticoids Phase 4,Phase 2
49
protease inhibitors Phase 4,Phase 2,Phase 3
50 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 1007)
id Name Status NCT ID Phase
1 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4
2 Antiviral Efficacy of Switching to ETV Plus TDF Unknown status NCT01597934 Phase 4
3 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
4 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
5 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
6 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
7 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
8 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
9 EFFORT Extension Study Unknown status NCT01529255 Phase 4
10 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
11 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4
12 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4
13 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
14 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4
15 Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission Unknown status NCT00939068 Phase 4
16 3E Extension Study Unknown status NCT01834508 Phase 4
17 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
18 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
19 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
20 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4
21 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4
22 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
23 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4
24 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
25 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
26 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
27 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
28 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
29 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
30 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B Unknown status NCT01913431 Phase 4
31 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4
32 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4
33 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4
34 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4
35 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4
36 HBsAg Related Response Guided Therapy Unknown status NCT01456312 Phase 4
37 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4
38 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
39 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
40 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
41 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4
42 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4
43 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4
44 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
45 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4
46 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4
47 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB Completed NCT01320943 Phase 4
48 Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine. Completed NCT00774995 Phase 4
49 Long-term Study With Clevudine Completed NCT00558818 Phase 4
50 Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases. Completed NCT00263614 Phase 4

Search NIH Clinical Center for Hepadnavirus Infection

Sources

Genetic Tests for Hepadnavirus Infection

About this section
Sources

Anatomical Context for Hepadnavirus Infection

About this section

MalaCards organs/tissues related to Hepadnavirus Infection:

39
Liver, T Cells
Sources

Publications for Hepadnavirus Infection

About this section

Articles related to Hepadnavirus Infection:

(show all 27)
id Title Authors Year
1
Serological and molecular evidence ofA hepadnavirus infection in swine. ( 25780820 )
2015
2
Animal Models and the Molecular Biology of Hepadnavirus Infection. ( 25833941 )
2015
3
Liver-directed gene therapy of chronic hepadnavirus infection using interferon alpha tethered to apolipoprotein A-I. ( 25772035 )
2015
4
Primary occult hepadnavirus infection induces virus-specific T-cell and aberrant cytokine responses in the absence of antiviral antibody reactivity in the Woodchuck model of hepatitis B virus infection. ( 19193791 )
2009
5
Immune selection during chronic hepadnavirus infection. ( 19669275 )
2008
6
Rapid production of neutralizing antibody leads to transient hepadnavirus infection. ( 14722274 )
2004
7
Frequency of spontaneous mutations in an avian hepadnavirus infection. ( 11559794 )
2001
8
Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. ( 11584382 )
2001
9
Hepadnavirus infection in captive gibbons. ( 10684318 )
2000
10
Antisense oligonucleotide therapy of hepadnavirus infection. ( 10565037 )
2000
11
Low dynamic state of viral competition in a chronic avian hepadnavirus infection. ( 10799602 )
2000
12
Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection. ( 10775634 )
2000
13
Mouse genetics at work: a new model of chronic hepadnavirus infection. ( 9657123 )
1998
14
Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. ( 9585237 )
1998
15
Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. ( 9419372 )
1998
16
Heterogeneous response for a mammalian hepadnavirus infection to acyclovir: drug-arrested intermediates of minus-strand viral DNA synthesis are enveloped and secreted from infected cells as virion-like particles. ( 8986943 )
1997
17
Absence of mutations in the p53 tumor suppressor gene in woodchuck hepatocellular carcinomas associated with hepadnavirus infection and intake of aflatoxin B1. ( 9006107 )
1996
18
Therapy of hepadnavirus infection using antisense oligonucleotides. ( 8666519 )
1995
19
Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. ( 8230462 )
1993
20
A preliminary report of a controlled study of thymosin alpha-1 in the woodchuck model of hepadnavirus infection. ( 1514437 )
1992
21
Cellular and molecular mechanisms of hepatocarcinogenesis associated with hepadnavirus infection. ( 1893774 )
1991
22
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: immunochemical analysis of woodchuck alpha-fetoprotein and measurement in serum by quantitative monoclonal radioimmunoassay. ( 1693355 )
1990
23
X antigen/antibody markers in hepadnavirus infections. Antibodies to the X gene product(s). ( 2365196 )
1990
24
X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum. ( 2311861 )
1990
25
Alpha-fetoprotein in the woodchuck model of hepadnavirus infection and disease: normal physiological patterns and responses to woodchuck hepatitis virus infection and hepatocellular carcinoma. ( 1701355 )
1990
26
Liver diseases associated with hepadnavirus infection. A study in duck model. ( 2620307 )
1989
27
Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. ( 3485201 )
1986
Sources

Variations for Hepadnavirus Infection

About this section
Sources

Expression for Hepadnavirus Infection

About this section
Search GEO for disease gene expression data for Hepadnavirus Infection.
Sources

Pathways for Hepadnavirus Infection

About this section
Sources

GO Terms for Hepadnavirus Infection

About this section
Sources

Sources for Hepadnavirus Infection

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....